Privi Speciality Chemicals Ltd

Privi Speciality Chemicals Q1 FY27: Revenue Growth & Major Capacity Expansion Roadmap 📈🏭

- Q1 FY27 revenue was Rs. 666 crore, representing a year-on-year growth of 19.22%.

- Consolidated total income for the quarter was Rs. 681.42 crores, a growth of 20.01% year-on-year.

- Consolidated EBITDA was Rs. 167.47 crores, with a margin of 24.58%.

- Profit After Tax (PAT) for the quarter was Rs. 83.2 crores, compared to Rs. 61.46 crores in Q1 FY26.

- Phase-1 capacity expansion is set to be commercialized shortly, increasing production capacity from 48,000 to 54,000 metric tons.

- Phase-2 and Phase-3 of the multi-specialty aroma chemicals project are progressing, with Phase-2 expected to be completed by September 2027, taking total capacity to 66,000 metric tons.

- The company has filed the merger scheme for Privi Speciality Chemicals, Privi Fine Sciences, and Privi Biotechnologies with the NCLT and expects completion within FY27.

- Net debt as of June 2026 was Rs. 865 crores, with a net debt-to-EBITDA ratio of 1.29 and a net debt-to-equity ratio of 0.57x.

- The working capital cycle improved to 108 days from 141 days in the previous year.

- Return on Equity (ROE) was 21.7% and Return on Capital Employed (ROCE) was 22.72% for the quarter.

- The company reiterated its long-term vision to achieve Rs. 5,000 crores in revenue and Rs. 1,000 crores plus EBITDA within the next three to four years.

- The PRIGIV joint venture generated revenue of approximately Rs. 18 crores with an EBITDA margin of 14%-15% in Q1.

- Capacity utilization across the company's plants is approximately 90%.

- The company is developing a 2-ton per day biomass demonstration plant in Navi Mumbai as part of its biotechnology initiatives.

- Key new product developments include Maltol, Ethyl Maltol, Ethylene brassylate (Musk T), and Cyclopentanone, with commercial contributions expected from H2 of the next financial year.